Skip to content

Study · Randomized controlled trial · n = 35 · 2002

4 results

High dose growth hormone treatment induces acceleration of skeletal maturation and an earlier onset of puberty in children with idiopathic short stature.

Kamp GA, Waelkens JJ, de Muinck Keizer-Schrama SM, Delemarre-Van de Waal HA, Verhoeven-Wind L, Zwinderman AH, Wit JM

Archives of disease in childhood1 Sept 2002Cited by 70 (Europe PMC)

PMID12193430 (opens in a new tab)PMCIDPMC1719235 (opens in a new tab)DOI10.1136/adc.87.3.215 (opens in a new tab)PepBankPUB-12193430
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In children with idiopathic short stature, bone maturation was 3.6 years/2 years with GH versus 2 years/2 years in controls.

    In plain wordsIn children with idiopathic short stature, bones matured faster with GH than in controls.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseBone maturation
    Study

    n = 35

    Comparator
    Control
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    6.0 IU/m2/day · Two yearsAs given in this study (human).

    Measurements

    Bone maturation
    3.6 years/2 years
    GH-treated children
    Bone maturation
    2 years/2 years
    controls

    Source sentences

    Summary
    A rapid rate of bone maturation of 3.6 years/2 years in treated children compared to 2 years/2 years in controls was observed in response to two years high dose GH treatment.
    2 context sentences
    Summary · context
    Twenty six boys and nine girls were randomly assigned to a GH treatment group (n = 17) or a control group (n = 18).
    Summary · context
    High dose GH treatment (6.0 IU/m2/day) was then started and continued for at least two full years.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In children with idiopathic short stature, height SDS for bone age did not differ significantly between GH and control groups.

    In plain wordsIn children with idiopathic short stature, height SDS for bone age did not differ significantly between GH and controls.

    Peptide
    HGH (somatotropin)
    Outcome
    No significant changeHeight SDS for bone age
    Study

    n = 35

    Comparator
    Control
    Outcome group
    Linear growth · Musculoskeletal
    Studied dose
    6.0 IU/m2/day · at least two years of high-dose GHAs given in this study (human).

    Source sentences

    Summary
    Height SDS for bone age was not significantly different between groups during the study period.
    2 context sentences
    Summary · context
    Twenty six boys and nine girls were randomly assigned to a GH treatment group (n = 17) or a control group (n = 18).
    Summary · context
    High dose GH treatment (6.0 IU/m2/day) was then started and continued for at least two full years.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In children with idiopathic short stature, GH recipients entered puberty significantly earlier than controls.

    In plain wordsIn children with idiopathic short stature, GH recipients entered puberty earlier than controls.

    Peptide
    HGH (somatotropin)
    Outcome
    DecreaseAge at puberty
    Study

    n = 35

    Comparator
    Control
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    6.0 IU/m2/day · at least two years of high-dose GHAs given in this study (human).

    Source sentences

    Summary
    GH treated children entered into puberty at a significantly earlier age compared to controls.
    2 context sentences
    Summary · context
    Twenty six boys and nine girls were randomly assigned to a GH treatment group (n = 17) or a control group (n = 18).
    Summary · context
    High dose GH treatment (6.0 IU/m2/day) was then started and continued for at least two full years.
  4. 04HumanNon-randomized trialEfficacy outcome

    In children with idiopathic short stature, GH increased height SDS from -2.6 (0.5) to -1.3 (0.5) after two years and -1.4 (0.5) after five years.

    In plain wordsIn children with idiopathic short stature, GH increased height SDS from baseline.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseHeight SDS for chronological age
    Study

    n = 17

    Outcome group
    Linear growth · Musculoskeletal
    Studied dose
    6.0 IU/m2/day · at least two years of high-dose GHAs given in this study (human).

    Measurements

    Height SDS for chronological age
    −2.6 SDS
    GH group, baseline, SD 0.5
    Height SDS for chronological age
    −1.3 SDS
    GH group, after 2 years, SD 0.5
    Height SDS for chronological age
    −1.4 SDS
    GH group, after 5 years, SD 0.5

    Source sentences

    Summary
    In response to at least two years on high dose GH treatment, mean (SD) height SDS for chronological age increased significantly in GH treated children from -2.6 (0.5) to -1.3 (0.5) after two years and -1.4 (0.5) SDS after five years of study.
    2 context sentences
    Summary · context
    Twenty six boys and nine girls were randomly assigned to a GH treatment group (n = 17) or a control group (n = 18).
    Summary · context
    High dose GH treatment (6.0 IU/m2/day) was then started and continued for at least two full years.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.